A War on High Drug Prices Could Boost Biosimilars Motley Fool
Putting an end to drug rebates to insurers could kick-start the use of low-cost biosimilar medications.
A War on High Drug Prices Could Boost Biosimilars Motley Fool
Putting an end to drug rebates to insurers could kick-start the use of low-cost biosimilar medications.